Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse‐free survival in acute myeloid leukemia
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27429 ↗Kurz gefasst
Leserbrief in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Metodi Balev und 12 weiteren Autor:innen. Beteiligte Einrichtung: Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 6 Literaturangaben.
Abstract (Originalsprache)
Multivariable analysis for overall survival and relapse-free survival demonstrating lack of significant for D14 BM status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York, USA.
ORCID-Profile: Metodi Balev
Zitieren
APA
Balev, M., Zibara, V., Van Hyfte, G., Feld, J., Kremyanskaya, M., Becker, M., Keyzner, A., Shih, A. H., Marcellino, B., Levavi, H., Silverman, L., Mascarenhas, J., & Tremblay, D. (2024). Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse‐free survival in acute myeloid leukemia. American Journal of Hematology. https://doi.org/10.1002/ajh.27429
Vancouver
Balev M, Zibara V, Van Hyfte G, Feld J, Kremyanskaya M, Becker M, et al. Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse‐free survival in acute myeloid leukemia. American Journal of Hematology. 2024. doi:10.1002/ajh.27429
BibTeX
@article{Balev2024,
author = {Balev, Metodi and Zibara, Victor and Van Hyfte, Grace and Feld, Jonathan and Kremyanskaya, Marina and Becker, Michelle and Keyzner, Alla and Shih, Alan H and Marcellino, Bridget and Levavi, Hannah and Silverman, Lewis and Mascarenhas, John and Tremblay, Douglas},
title = {Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse‐free survival in acute myeloid leukemia},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27429}
}
EUVIMED